请使用支持JavaScript的浏览器!
主营:分子类,蛋白类,抗体类,生化类试剂
℡ 4000-520-616
℡ 4000-520-616
Selleck Chemicals/Fedratinib (TG101348)/S2736
产品编号:S2736
市  场 价:¥11400.00
场      地:美国(厂家直采)
产品分类: 蛋白类>多肽>多肽合成>
联系QQ:1570468124
电话号码:4000-520-616
邮      箱: info@ebiomall.com
美  元  价:$570.00
品      牌: Selleck Chemicals
公      司:Selleckchem
公司分类:
Selleck Chemicals/Fedratinib (TG101348)/S2736
商品介绍
DescriptionFedratinib (SAR302503, TG101348) is a selective inhibitor of JAK2 with IC50 of 3 nM in cell-free assays, 35- and 334-fold more selective for JAK2 versus JAK1 and JAK3. Fedratinib also inhibits FMS-like tyrosine kinase 3 (FLT3) and RET (c-RET) with IC50 of 15 nM and 48 nM, respectively. Fedratinib has potential antineoplastic activity. Fedratinib inhibits proliferation and induces apoptosis. Phase 2.
Targets
JAK2 [1](Cell-free assay)JAK2 (V617F) [1](Cell-free assay)FLT3 [1](Cell-free assay)RET [1](Cell-free assay)
3 nM3 nM15 nM48 nM
In vitro

TG-101348 also significantly inhibits JAK2 V617F, Flt3, and Ret with IC50 of 3 nM, 15 nM, and 48 nM, respectively. TG101348 has an IC50 ~300-fold higher for the closely related JAK3 and is a less potent inhibitor of the JAK1 and TYK2 family members. TG101348 inhibits proliferation of a human erythroblast leukemia (HEL) cell line that harbors the JAK2V617F mutation, as well as a murine pro-B cell line expressing human JAK2V617F (Ba/F3 JAK2V617F), with IC50 of 305 nM and 270 nM, respectively. TG-101348 also inhibits proliferation of parental Ba/F3 cells to a comparable level, with IC50 of ~420 nM. TG101348 treatment reduces STAT5 phosphorylation at concentrations that parallel the concentrations required to inhibit cell proliferation. TG101348 induces apoptosis in both HEL and Ba/F3 JAK2V617F cells in a dose-dependent manner. TG101348 does not show proapoptotic activity in control normal human dermal fibroblasts at concentrations up to 10 μM, and the antiproliferative IC50 against fibroblasts is >5 μM. [1] TG101348 treatment decreases GATA-1 expression, which is associated with erythroid-skewing of JAK2V617F+ progenitor differentiation, and inhibits STAT5 as well as GATA S310 phosphorylation. [2] TG101348 inhibits the proliferation of HMC-1.1 (KITV560G) cells, with somewhat lower potency than HMC-1.2 (KITD816V, KITV560G) cells, with IC50 of 740 nM and 407 nM, respectively. [3]

Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
H1975MnzkRZBweHSxc3nzJGF{e2G7MniyNE42NTJizszNNVq1S44yOTJvNEigbC=>MWrEUXNQMYfpcoR2[2W|IHHwc5B1d3OrczDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNSCmZYDlcoRmdnRibXHucoVzNIraPFU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJuWRwbnPibU5vdG1wbnnoModwfi9{NUi2PVIyOCd-MkW4OlkzOTB:L3G+
H1650M4TR[GFxd3C2b4Ppd{BCe3OjeR?=NYPIbXdHOC53LUKg{txOMnqzNVIuPDhiaB?=MWDEUXNQMULpcoR2[2W|IHHwc5B1d3OrczDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNSCmZYDlcoRmdnRibXHucoVzNWTPXY9sRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4OlkzOTBpPkK1PFY6OjFyPD;hQi=>
H1975MWDGeY5kfGmxbjDBd5NigQ>?NVHLenI4OC5{NT2xJO69VQ>?NFr4XVAzPCCqM1jxRmROW09?M2rWTYlvcGmkaYTzJIV5eHKnc4Ppc44hd2ZiYYDvdJRwe2m|LYLlcIF1WRicILveIVqdiCEY3ytXGwtKEKlbD2yMEB{fXK4aYpckwhYEmDUB?=MUe8ZUB1[XKpZYS9K39jdGGwazegbJJmj1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh4OUKxNEc,OjV6NkmyNVA9N2F-
H1650NITONnZHfW6ldHnvckBCe3OjeR?=MUGwMlI2NTFizszNNEfTR20zPCCqMUXEUXNQMVTpcohq[mm2czDlfJBzXO|aX;uJI9nKGGyb4D0c5Nqey2{ZXzheIVlKHC{b4TlbY4hSmOuLWjMMEBD[2xvMjygd5Vzfmm4aX6sJHhKSVB?M4LOVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1mC6wY3LpMo5tdS6waXiu[493NzJ3OE[5NlExLz5{NUi2PVIyODxxYU6=
H1975M{TNNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXuxJO69VQ>?NYHUPJlTPDhiaB?=MoHkSG1UVw>?NUjSTXZse2Wwc3n0bZpmeyClZXzsd{B1dyC2aHWgZ5l1d3SxeHnjbZR6KG:oIHXycI91cW6rYh?=MVe8ZUB1[XKpZYS9K39jdGGwazegbJJmj1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh4OUKxNEc,OjV6NkmyNVA9N2F-
H1650NYSxVHM5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYrXVpo4OSEQvF2=MmnHOFghcA>?NXT1fW45TE2VTx?=Mn7Bd4Vve2m2aYrld{BkWyuczD0c{B1cGViY4n0c5RwgGmlaYT5JI9nKGW{bH;0bY5q[g>?NYPES5hrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4OlkzOTBpPkK1PFY6OjFyPD;hQi=>
CD4+TMmC5SpVv[3Srb36gRZN{[Xl?MXqwMlAyNTFizszNMoLpOFghcA>?MnTUSG1UVw>?NET4UFFzWS3Y3XzJJRpSCyaH;zdIhwenmuYYTpc44hdGW4ZXzzJI9nKEqDS{KgZY5lKFOWQWSzxsA>Moj4QIEhfGG{Z3X0QUdg[myjbnunJIhzWZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3N{K1N|UoRjJ3NUeyOVM2RC:jPh?=
Caco-2NVnrPYxUTnWwY4Tpc44hSXO|YYm=M4fvbFAuOTJyIN88US=>NWrP[5lLPyCvaX6=MUDpcohq[mm2czD0bIlidWmwZTD1dJRic2Vid3n0bEBidiCLQ{WwxsBwiB{LkJCpOK2VQ>?M23bFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1mC6wY3LpMo5tdS6waXiu[493NzJ3ME[zOlczLz5{NUC2N|Y4OjxxYU6=
Caco-2M2HWT2Z2dmO2aX;uJGF{e2G7Ml73NVAwPTBxMUCwJO69VQ>?NVPGUXV[OiCqMmjM[IVkemWjc3XzJJRpSCobIX4JI9nKFt|SG30bIlidWmwZTDhZ5Jwe3NidHjlJI1wdm:uYYnldkB4cXSqIFnDOVAhd2ZiNj61xsDPxE1?MkDRQIEhfGG{Z3X0QUdg[myjbnunJIhzWZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNkO2O|IoRjJ3ME[zOlczRC:jPh?=
HEK293 MSRNILrTVJHfW6ldHnvckBCe3OjeR?=NV;GeVdEOC1zMDFOwG0>MYW3JI1qdg>?NWnp[GRrcW6qaXLpeJMhcFSKVGKyJJdqfGhiYX6gTWM2OMLib3[gNU4zyqEEtV2=MUS8ZUB1[XKpZYS9K39jdGGwazegbJJmj1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB4M{[3Nkc,OjVyNkO2O|I9N2F-
MedB-1MowSpVv[3Srb36gRZN{[Xl?NHn6NG8yNzJizszNM4m0NlI1KGh?NV7OdWV3GWlcnXhd4V{KFOWQWS2JJBpd3OyaH;yfYxifGmxbjDjc45kW62cnH0bY9vKGSncHXu[IVvfGy7MV28ZUB1[XKpZYS9K39jdGGwazegbJJmj1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl5N{[2PEc,OjR7N{e2Olg9N2F-
U2940NULDT3g4TnWwY4Tpc44hSXO|YYm=MVGxM|Ih|ryPNFLDb40zPCCqMmPX[IVkemWjc3XzJHNVSVR4IIDoc5NxcG:{eXzheIlwdiClb37j[Y51emG2aX;uJIRmeGWwZHXueIx6Mn7rQIEhfGG{Z3X0QUdg[myjbnunJIhzWZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7N{e2OlgoRjJ2OUe3OlY5RC:jPh?=
K1106M162TmZ2dmO2aX;uJGF{e2G7M2DsblEwOiEQvF2=M3G0R|I1KGh?MX7k[YNzWG|ZYOgV3RCXDZicHjvd5Bpd3K7bHH0bY9vKGOxbnPlcpRz[XSrb36g[IVxW6mZX70cJk>MnnRQIEhfGG{Z3X0QUdg[myjbnunJIhzWZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7N{e2OlgoRjJ2OUe3OlY5RC:jPh?=
K562NFr0U5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlfoNE0yKM7:TR?=MY[3NkBpMVnpcohq[mm2czDLOVYzKGOnbHygdJJwdGmoZYLheIlwdiCjdDDobYdpKGOxbnPlcpRz[XSrb36=NY[2bWZyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3O|U{ODhpPkK0O|c2OzB6PD;hQi=>
MDA-MB-468NXywSndvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXOzJOK2VQ>?MX60PEBpM3T0OYVvcGGwY3XkJJNq[mOuNjDpcoR2[2WmIHzvd5Mhd2ZiY3XscEB3cWGkaXzpeJnDqA>?MXm8ZUB1[XKpZYS9K39jdGGwazegbJJmj1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ4MkixPEc,OjR4NkK4NVg9N2F-
MDA-MB-468MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIruZZExNTRizszNMWq0PEBpM4 OZJme3WudIOgd4lodmmoaXPhcpQhdG:|czDv[kB3cWGkaXzpeJkh[2:vcHHy[YQhfG9iUlmtRnBKKGGub37lM1roflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1mC6wY3LpMo5tdS6waXiu[493NzJ2Nk[yPFE5Lz5{NE[2NlgyQDxxYU6=
L428NH[zRpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MY[wMVUh|ryPNEnTbHE1QCCqNYXST4xUcW6qaXLpeJMh[2WubDDndo94fGhic3nncolncWOjboTsfS=>M3fCelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1mC6wY3LpMo5tdS6waXiu[493NzJ2NkGwPFI4Lz5{NE[xNFgzPzxxYU6=
KMH2MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWCwMVUh|ryPMXq0PEBpMWXpcohq[mm2czDj[YxtKGe{b4f0bEB{cWewaXpZ4FvfGy7MX:8ZUB1[XKpZYS9K39jdGGwazegbJJmj1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZzMEiyO{c,OjR4MUC4Nlc9N2F-
L1236Mo[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEf3d40xNTVizszNNH2xeYY1QCCqNHvaXW9qdmirYnn0d{BkWyuIHfyc5d1cCC|aXfubYZq[2GwdHz5NETrSmM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJuWRwbnPibU5vdG1wbnnoModwfi9{NE[xNFgzPyd-MkS2NVA5Ojd:L3G+
SUPHD1MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmDhNE02KM7:TR?=NGIdos1QCCqNVSwVpJUcW6qaXLpeJMh[2WubDDndo94fGhic3nncolncWOjboTsfS=>NVPJfWNlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2NVA5OjdpPkK0OlExQDJ5PD;hQi=>
HDLM2MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlXYNE02KM7:TR?=M4D1[FQ5KGh?MVzpcohq[mm2czDj[YxtKGe{b4f0bEB{cWewaXpZ4FvfGy7NH3xeYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJuWRwbnPibU5vdG1wbnnoModwfi9{NE[xNFgzPyd-MkS2NVA5Ojd:L3G+
K1106PNF7n[ZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUSwMVUh|ryPNGH2N2c1QCCqM2rE[IlvcGmkaYTzJINmdGxiZ4Lve5RpKHOrZ37p[olk[W62bIm=Mn QIEhfGG{Z3X0QUdg[myjbnunJIhzWZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4MUC4NlcoRjJ2NkGwPFI4RC:jPh?=
L428MYXBdI9xfG:|aYOgRZN{[Xl?NXH5cGZbOC9yLk[yOU8yNjJ3IN88US=>NIPMeY81QCCqMVpcoR2[2W|IITo[UBieG:ydH;zbZPDqA>?NYezNXVrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2NVA5OjdpPkK0OlExQDJ5PD;hQi=>
KMH2NUHTe3l7SXCxcITvd4l{KEG|c3H5M1r3TlAwOC54MkWvNU4zPSEQvF2=MmnQOFghcA>?Ml3PbY5lfWOnczD0bIUh[XCxcITvd4l{yqB?M4nFN|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1mC6wY3LpMo5tdS6waXiu[493NzJ2NkGwPFI4Lz5{NE[xNFgzPzxxYU6=
L1236NXzIfGJJSXCxcITvd4l{KEG|c3H5NEXNc|kxNzBwNkK1M|EvOjVizszNMkKwOFghcA>?M1;DVIlvHWlZYOgeIhmKGGyb4D0c5Nqe8LiNHSwVZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJuWRwbnPibU5vdG1wbnnoModwfi9{NE[xNFgzPyd-MkS2NVA5Ojd:L3G+
SUPHD1NFfYW4RCeG:ydH;zbZMhSXO|YYm=MV[wM|AvPjJ3L{GuNlUh|ryPNVnYSW5ZPDhiaB?=Mn7PbY5lfWOnczD0bIUh[XCxcITvd4l{yqB?M333SlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1mC6wY3LpMo5tdS6waXiu[493NzJ2NkGwPFI4Lz5{NE[xNFgzPzxxYU6=
HDLM2Mkf3RZBweHSxc3nzJGF{e2G7MlzvNE8xNjZ{NT:xMlI2KM7:TR?=NHjzNWc1QCCqMnnPbY5lfWOnczD0bIUh[XCxcITvd4l{yqB?M1jnXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1mC6wY3LpMo5tdS6waXiu[493NzJ2NkGwPFI4Lz5{NE[xNFgzPzxxYU6=
K1106PMoKwRZBweHSxc3nzJGF{e2G7MWmwM|AvPjJ3L{GuNlUh|ryPM2HDZ|Q5KGh?NWX5[YhIcW6mdXPld{B1cGViYYDvdJRwe2m|wrC=M1qxS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1mC6wY3LpMo5tdS6waXiu[493NzJ2NkGwPFI4Lz5{NE[xNFgzPzxxYU6=
L428MXfGeY5kfGmxbjDBd5NigQ>?MWGwMVUh|ryPMXWyOEBpMULpcohq[mm2czDKRWszN1OWQWSgd4lodmGuaX7nNGT2bHE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJuWRwbnPibU5vdG1wbnnoModwfi9{NE[xNFgzPyd-MkS2NVA5Ojd:L3G+
KMH2M2TGbGZ2dmO2aX;uJGF{e2G7MmfHNE02KM7:TR?=Moq1NlQhcA>?MnHRbY5pcWKrdIOgTmFMOi:VVFHUJJNq26jbHnu[y=>MYq8ZUB1[XKpZYS9K39jdGGwazegbJJmj1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZzMEiyO{c,OjR4MUC4Nlc9N2F-
L1236NWTBU|BMTnWwY4Tpc44hSXO|YYm=M3qZVAuPSEQvF2=MViyOEBpMVTpcohq[mm2czDKRWszN1OWQWSgd4lodmGuaX7nM2PtUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1mC6wY3LpMo5tdS6waXiu[493NzJ2NkGwPFI4Lz5{NE[xNFgzPzxxYU6=
SUPHD1MVGeY5kfGmxbjDBd5NigQ>?M2m5PVAuPSEQvF2=NGrxVYozPCCqNUfrVlR6cW6qaXLpeJMhUkGNMj;TWGFVKHOrZ37hcIlvw>?NVPxdFJIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2NVA5OjdpPkK0OlExQDJ5PD;hQi=>
HDLM2NXjB[IZVTnWwY4Tpc44hSXO|YYm=NUHKPGNQOC13IN88US=>NInafmUzPCCqNVu5eJR1cW6qaXLpeJMhUkGNMj;TWGFVKHOrZ37hcIlvw>?NF21UGQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJuWRwbnPibU5vdG1wbnnoModwfi9{NE[xNFgzPyd-MkS2NVA5Ojd:L3G+
K1106PMnrJSpVv[3Srb36gRZN{[Xl?M2fZdFAuPSEQvF2=NHvqfHMzPCCqNUjYcYx1cW6qaXLpeJMhUkGNMj;TWGFVKHOrZ37hcIlvw>?MoHpQIEhfGG{Z3X0QUdg[myjbnunJIhzWZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4MUC4NlcoRjJ2NkGwPFI4RC:jPh?=
MM.1SMUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXLibohrUUN3ME2xMVMh|ryPNEPTOWs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJuWRwbnPibU5vdG1wbnnoModwfi9{NEW4OFExOSd-MkS1PFQyODF:L3G+
TpoR JAK2 WTMYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVG0b4tQUUN3ME2xMlQhMDFwM,MAl|EvPSlizszNNVLyRmtHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyOVE4QTBpPkK0NlUyPzlyPD;hQi=>
TpoR JAK2 V617FMl:zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFWzfoFKSzVyPUCuPEApOC554pETNE46MSEQvF2=NWCbWFPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyOVE4QTBpPkK0NlUyPzlyPD;hQi=>
TpoR W515LNVXmN|BTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mln0TWM2OD1yLkigLFAvP+LCk{GuNEkh|ryPMVy8ZUB1[XKpZYS9K39jdGGwazegbJJmj1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ3MUe5NEc,OjR{NUG3PVA9N2F-
Bcr-ablNEPtdI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorNTWM2OD1{LkegLFIvOuLCk{OuN{kh|ryPNYDUTJFmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyOVE4QTBpPkK0NlUyPzlyPD;hQi=>
JAK2 TWNWPFfVZrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MliyTWM2OD1zLkigLFEvPeLCk{KuN{kh|ryPNGHu[Yg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJuWRwbnPibU5vdG1wbnnoModwfi9{NEK1NVc6OCd-MkSyOVE4QTB:L3G+
JAK2 V617FMYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVjJR|UxRTBwNjCoNE436oDVMD63LUDPxE1?MWq8ZUB1[XKpZYS9K39jdGGwazegbJJmj1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ3MUe5NEc,OjR{NUG3PVA9N2F-
MedB-1NUjlS4xiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3P5Z|Qh|ryPM33POVI1NzR6L{eyJIg>NIPc|NFVVORMXrpcohq[mm2czDj[YxtKGe{b4f0bEB1cW2nIHTldIVvGWwdHz5M1fXV|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1mC6wY3LpMo5tdS6waXiu[493NzJ|OEWyN|Y3Lz5{M{i1NlM3PjxxYU6=
K1106NILEVWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUe0JO69VQ>?MWCyOE81QC95MjDoNYeyV2JvTE2VTx?=NYrMOFFCcW6qaXLpeJMh[2WubDDndo94fGhidHnt[UBlXCnbnTlcpRtgQ>?MX28ZUB1[XKpZYS9K39jdGGwazegbJJmj1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh3MkO2Okc,OjN6NUKzOlY9N2F-
U2940MoxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXW0JO69VQ>?MkXGNlQwPDhxN{KgbC=>NWT5WGk5TE2VTx?=MUDpcohq[mm2czDj[YxtKGe{b4f0bEB1cW2nIHTldIVvGWwdHz5NIHHTG09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJuWRwbnPibU5vdG1wbnnoModwfi9{M{i1NlM3Pid-MkO4OVI{PjZ:L3G+
FE-PDMmLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{HJdlAvODZ|LUSg{txOM3;4OmlEPTB;OT61JO69VSxiaX7obYJqfHNiY3XscEBoem:5dHig[I9{SCmZYDlcoRmdnSueR?=NGnxe4E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJuWRwbnPibU5vdG1wbnnoModwfi9{M{O3NlY3QSd-MkOzO|I3Pjl:L3G+
HELMkjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlPjNE4xPjNvNDFOwG0>NXm0TWtwUUN3ME2xMlUh|ryPLDDpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVvGWwdHz5MWS8ZUB1[XKpZYS9K39jdGGwazegbJJmj1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN5Mk[2PUc,OjN|N{K2Olk9N2F-
K-562NXHOcWlpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYrvcXp7OC5yNkOtOEDPxE1?M2HidGlEPTB;Mj61JO69VSxiaX7obYJqfHNiY3XscEBoem:5dHig[I9{SCmZYDlcoRmdnSueR?=NXW1cnZQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzO|I3PjlpPkKzN|czPjZ7PD;hQi=>
L-82 M3znfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3vYZlAvODZ|LUSg{txOM4Ha[GlEPTB;MD65PEDPxE1uIHnubIljcXS|IHPlcIwh3Kxd4ToJIRwe2ViZHXw[Y5lW62bIm=MVi8ZUB1[XKpZYS9K39jdGGwazegbJJmj1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN5Mk[2PUc,OjN|N{K2Olk9N2F-
MAC-1MmjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1nFOlAvODZ|LUSg{txOMYrJR|UxRTBwNUKg{txONCCrbnjpZol1eyClZXzsJIdzd3e2aDDkc5NmKGSncHXu[IVvfGy7NWPEVW9qRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzO|I3PjlpPkKzN|czPjZ7PD;hQi=>
MAC-2AM330VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mom3NE4xPjNvNDFOwG0>NGHJeolKSzVyPUCuOlkh|ryPLDDpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVvGWwdHz5Mn3KQIEhfGG{Z3X0QUdg[myjbnunJIhzWZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN|N{K2OlkoRjJ|M{eyOlY6RC:jPh?=
MAC-2BNITWTJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1PZZlAvODZ|LUSg{txOMXjJR|UxRTBwNUSg{txONCCrbnjpZol1eyClZXzsJIdzd3e2aDDkc5NmKGSncHXu[IVvfGy7M1zqT|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1mC6wY3LpMo5tdS6waXiu[493NzJ|M{eyOlY6Lz5{M{O3NlY3QTxxYU6=
MY-LAM{fnNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3zhS|AvODZ|LUSg{txOM2XGR2lEPTB;Mj6xJO69VSxiaX7obYJqfHNiY3XscEBoem:5dHig[I9{SCmZYDlcoRmdnSueR?=MmHzQIEhfGG{Z3X0QUdg[myjbnunJIhzWZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN|N{K2OlkoRjJ|M{eyOlY6RC:jPh?=
NC-NCMVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3HTR|AvODZ|LUSg{txOMYjJR|UxRTFwMDFOwG0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHTvd4UhGWyZX7k[Y51dHl?NFvJc4M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJuWRwbnPibU5vdG1wbnnoModwfi9{M{O3NlY3QSd-MkOzO|I3Pjl:L3G+
SE-AXMWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4Pke|AvODZ|LUSg{txOMmPsTWM2OD1zLkWg{txONCCrbnjpZol1eyClZXzsJIdzd3e2aDDkc5NmKGSncHXu[IVvfGy7NYjLVllmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzO|I3PjlpPkKzN|czPjZ7PD;hQi=>
SR-786NIf6cYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4fO[VAvODZ|LUSg{txONIjicpBKSzVyPUSuOkDPxE1uIHnubIljcXS|IHPlcIwh3Kxd4ToJIRwe2ViZHXw[Y5lW62bIm=MVi8ZUB1[XKpZYS9K39jdGGwazegbJJmj1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN5Mk[2PUc,OjN|N{K2Olk9N2F-
M-MOKM1yyTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF7YT2UzPSEEtV5CpC=>MoTnNlQwPDhxN{KgbC=>NELweJNFVVORNYPJepk4cW6qaXLpeJMh[2WubDDndo94fGhidHnt[UBlXCnbnTlcpRtgQ>?NVjBR21zRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG4OVMyPTdpPkKxPFU{OTV5PD;hQi=>
HELNX3ad3VKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX;Bd2x5UUN3ME2zNFUhdk1?MW[8ZUB1[XKpZYS9K39jdGGwazegbJJmj1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDN7NEW1OEc,OTh|OUS1OVQ9N2F-
Ba/F3 JAK2V617FM2fmUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWTJR|UxRTJ5MDDuUS=>M13BZ|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1mC6wY3LpMo5tdS6waXiu[493NzF6M{m0OVU1Lz5zOEO5OFU2PDxxYU6=
MV4-11MWHBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?MlnEO|IhcHK|M1rvXWFvfGmycn;sbYZmemG2aYlJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTW[0MVEyKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDj[YxtfGm2ZYKtZox2SCjc4PhfUwhTUN3MDC9JFAvODd7IN88UU4>NICxTW09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJuWRwbnPibU5vdG1wbnnoModwfi9{OEK4NFI3OSd-MkiyPFAzPjF:L3G+
MM1SNV;4cFZZSW62aYDyc4xqmW{YYTpeoUh[XO|YYm=NULKRXVrPzJiaILzM{TzbmFvfGmycn;sbYZmemG2aYlJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTV2xV{BkWyuczDh[pRmeiB5MjDodpMh[nlidIL5dIFvKGKudXWg[ZhkdHW|aX;uJIF{e2G7LDDJR|UxKD1iMTFOwG0vMXq8ZUB1[XKpZYS9K39jdGGwazegbJJmj1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MEK2NUc,Ojh{OECyOlE9N2F-
NB1643NXvWNIVneUiWUzDhd5NigQ>?MlP2dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5IhHK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6EMU[0N{BkWyucx?=M3TJTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1mC6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-MCNGmXXRyUFSVIHHzd4F6NIPFXnByUFSVIH;mJJBmGmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBtSCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1OSyClZXzsdy=>MVO8ZUB1[XKpZYS9K39jdGGwazegbJJmj1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-

... Click to View More Cell Line Experimental Data

Assay
MethodsTest IndexPMID
Western blot
p-JAK2 / p-STAT1 / p-STAT3 / p-STAT6 / p-STAT5 / JAK2 ;

PubMed: 24610827

Western analysis of pJAK2 and the downstream pSTATs following treatment with vehicle or the indicated concentrations of fedratinib for 24 hours. Total JAK2 and GAPDH are similarly analyzed.

c-Myc / PIM1 ;

PubMed: 24610827

Western analysis of c-MYC and PIM1 protein levels in cHL and MLBCL cell lines treated with vehicle or fedratinib at the indicated concentration for 24 hours. Data are representative of three independent experiments.

24610827
Growth inhibition assay
Cell proliferation ;

PubMed: 24610827

Cellular proliferation of cHL cell lines (L428, KMH2, L1236, SUPHD1 and HDLM2) and the MLBCL cell line (K1106P), following treatment with vehicle or fedratinib at indicated concentration for 48 hours. For each cell line, the previously reported 9p24.1/JAK2 copy numbers (7) are indicated in parenthesis. At a given dose of the JAK2 inhibitor (1.25 μM), a Kruskal-Wallis test was performed to assess the association between the ranked values of inhibition and copy number gain (p = .009, cHL and MLBCL cell lines; p = .019, cHL cell lines).

24610827
In vivo

TG101348 has potential for efficacious treatment of JAK2V617F-associated myeloproliferative diseases (MPD). In treated animals, there is a statistically significant reduction in hematocrit and leukocyte count, a dose-dependent reduction/elimination of extramedullary hematopoiesis, and, at least in some instances, evidence for attenuation of myelofibrosis, correlated with surrogate endpoints, including reduction/elimination of JAK2V617F disease burden, suppression of endogenous erythroid colony formation, and in vivo inhibition of JAK-STAT signal transduction. There are no apparent toxicities and no effect on T cell number. [1] Oral administration of TG101348 (120 mg/kg) significantly inhibits PV progenitor erythroid differentiation in vivo. [2]

品牌介绍

Selleck Chemicals提供了超过120,000种用于细胞信号通路研究的抑制剂。我们积极跟踪最新科学,因此我们的客户可以依靠我们成为最新抑制剂的领先供应商。

Selleck的生物活性化合物库由8,000多个具有经过验证的生物学和药理活性的小分子组成。这些分子的安全性和有效性已通过临床前和临床研究证明,其中许多是FDA批准的化合物。


自营商城图标
厂家直采
全球直采 正品优价
正品保障图标
正品保障
厂家直发 有线跟踪
解放采购图标
正规清关
CIF100%正规报关,提供发票
及时交付图标
及时交付
限时必达 不达必赔